|
시장보고서
상품코드
1789394
세계의 GLP-1 유사체 시장 : 약제 유형별, 브랜드별, 용도별, 투여 경로별, 유형별, 성별, 연령층별, 유통 채널별, 지역별(2025-2032년)Glucagon Like Peptide 1 Analogs Market, By Drug Type,, By Brand,, By Application,, By Route of Administration,, By Type,, By Gender,, By Age Group,, By Distribution Channel,, By Geography |
||||||
세계의 GLP-1 유사체 시장은 2025년 535억 달러로 추정되며, 2032년까지 1,044억 4,000만 달러에 이를 것으로 예측되며, 예측 기간 중 CAGR 10.1%로 성장할 전망입니다.
| 보고 범위 | 보고서 세부정보 | ||
|---|---|---|---|
| 기준 연도 | 2024년 | 2025년 시장 규모 | 535억 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2025-2032년 |
| 예측 기간 : 2025-2032년 CAGR: | 10.10% | 2032년 금액 예측 | 1,044억 4,000만 달러 |
GLP-1 유사체 시장은 2형 당뇨병과 비만 관리 치료 패러다임을 근본적으로 변화시키는 당뇨병 치료제의 전망에서 혁명적인 부문입니다. GLP-1 유사체는 천연 발생 인크레틴 호르몬인 GLP-1의 합성물로 인슐린 분비를 자극하고 글루카곤 분비를 억제하며 위 배출을 지연시켜 포도당의 항상성 유지에 중요한 역할을 하고 있습니다. 이러한 혁신적인 치료제는 혈당 조절과 상당한 체중 감소라는 두 가지 작용기전을 겸비하기 때문에 기초 치료제로서 대두해 왔습니다.
이 시장에는 매일 1회 투여 제제, 주 1회 투여 제제, 장시간 작용형 제제 등 다양한 제제가 있으며, 환자의 취향과 치료 프로토콜의 다양성에 대응하고 있습니다. 주요 기업은 약효를 높이고 부작용을 줄이고 고급 전달 시스템을 통해 환자의 컴플라이언스를 향상시키기 위해 연구 개발에 많은 투자를 하고 있습니다. 세계 당뇨병 유병률 증가와 비만 관련 합병증에 대한 의식이 증가함에 따라 GLP-1 유사체는 건강 관리 제공업체들 사이에서 선호되는 치료 옵션으로 자리매김하고 있습니다. 이 시장 부문은 심혈관 위험 감소 및 신경보호 작용의 가능성 등 임상 응용의 확대를 통해 강력한 성장을 이어가고 있으며 현대 의약 업계에서 가장 역동적이고 빠르게 발전하는 분야 중 하나가 되었습니다.
시장 역학
GLP-1 유사체 시장은 강력한 성장 궤도를 뒷받침하는 몇 가지 강력한 촉진요인에 의해 지원됩니다. 첫 번째 요인은 2형 당뇨병과 비만세계의 유병률 상승으로, 현재 세계 5억 3,700만 명 이상의 성인이 당뇨병을 앓고 있으며 효과적인 치료 개입에 대한 전례없는 수요가 발생하고 있습니다. GLP-1 유사체의 탁월한 효능 프로파일은 상당한 체중 감소 효과와 함께 HbA1c의 유의한 감소를 나타내며, 이러한 약물은 기존의 당뇨병 치료제보다 선호되는 치료 옵션으로 자리매김하고 있습니다. 또한 심혈관 보호 작용과 비알코올성 지방 간 질환(NAFLD)에의 응용 가능성을 지지하는 임상 증거의 확대로 치료 영역의 폭이 넓어 시장 도입의 원동력이 되고 있습니다. 서방형 제형 및 혁신적인 주사 장치를 포함한 약물 전달 시스템의 기술적 진보는 환자의 편의성과 충동을 향상시키고 시장 성장을 더욱 자극합니다. 그러나 GLP-1 유사체 제제는 기존의 당뇨병 치료제에 비해 고가이기 때문에 특히 가격에 민감한 시장에서는 입수 장벽이 되고, 특정 지역에서는 보험 적용이 제한되는 등 시장은 현저한 억제요인에 직면하고 있습니다.
메스꺼움, 구토, 설사와 같은 소화 시스템의 부작용은 환자의 컴플라이언스 및 치료 지속에 영향을 미치고 시장 침투를 방해할 수 있습니다. 펩타이드 기반 생물학적 제제의 제조 복잡성은 공급망의 과제와 비용에 영향을 미칩니다. 그러나 의료 인프라의 개선과 보험 적용 범위의 확대와 함께 당뇨병 유병률이 급속히 상승하고 있는 신흥 경제 국가의 미개척 시장에서는 큰 비즈니스 기회가 탄생하고 있습니다. GLP-1 유사체와 다른 당뇨병 치료제와의 병용 요법의 가능성은 유리한 발전 기회를 가져옵니다. 또한 알츠하이머병, 파킨슨병 및 기타 대사성 질환을 포함한 신규 적응증 연구가 진행 중이며, GLP-1 유사체를 당뇨병 관리 이외의 다목적 치료 플랫폼으로 자리매김함으로써 대응 가능한 시장이 크게 확대될 수 있습니다.
본 조사의 주요 특징
- 본 보고서에서는 세계의 GLP-1 유사체 시장을 상세하게 분석하여 2024년을 기준 연도로 한 예측기간(2025-2032년) 시장 규모 및 복합 연간 성장률(CAGR%)을 보여줍니다.
- 또한 다양한 부문에 걸친 잠재적인 수익 기회를 밝히고 이 시장의 매력적인 투자 제안 매트릭스에 대해 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품의 상시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 중요한 고찰도 제공합니다.
- 엔터프라이즈 하이라이트, 제품 포트폴리오, 주요 하이라이트, 실적, 전략 등의 매개변수를 기반으로 세계의 GLP-1 유사체 시장의 주요 기업 프로파일을 제공합니다.
- 이 보고서의 통찰을 통해 마케팅 담당자와 기업 경영진은 향후 제품 상시, 타이핑, 시장 확대, 마케팅 전술에 대한 정보를 바탕으로 의사 결정을 내릴 수 있습니다.
- 이 조사 보고서는 투자자, 공급업체, 제품 제조업체, 판매자, 신규 참여자, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
목차
제1장 조사의 목적과 전제조건
- 조사 목적
- 전제조건
- 약어
제2장 시장 전망
- 보고서 설명
- 시장 정의와 범위
- 주요 요약
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 성장 촉진요인
- 억제요인
- 기회
- 영향 분석
- 주요 발전
- 규제 시나리오
- 제품 출시/승인
- PEST 분석
- Porter's Five Forces 분석
- 합병과 인수 시나리오
- 업계 동향
제4장 세계의 GLP-1 유사체 시장 : 약제 유형별, 2020-2032년
- 세마글루타이드
- 리라글루타이드
- 엑세나타이드
- 듀라글루타이드
- 틸제파타이드
- 리나글립틴
- 릭시세나타이드
- 기타
제5장 세계의 GLP-1 유사체 시장 : 브랜드별, 2020-2032년
- Saxenda
- Victoza
- Ozempic
- Wegovy
- Rybelsus
- Trulicity Pen
- Zepbound
- Mounjaro
- BYDUREON BCise
- 기타
제6장 세계의 GLP-1 유사체 시장 : 용도별, 2020-2032년
- 2형 당뇨병
- 체중 관리(비만 및 과체중)
- 심혈관 위험 경감
제7장 세계의 GLP-1 유사체 시장 : 투여 경로별, 2020-2032년
- 경구
- 비경구
제8장 세계의 GLP-1 유사체 시장 : 유형별, 2020-2032년
- 브랜드
- 제네릭
제9장 세계의 GLP-1 유사체 시장 : 성별, 2020-2032년
- 남성
- 여성
제10장 세계의 GLP-1 유사체 시장 : 연령층별, 2020-2032년
- 성인
- 소아
제11장 세계의 GLP-1 유사체 시장 : 유통 채널별, 2020-2032년
- 병원 약국
- 소매 약국
- 온라인 약국
제12장 세계의 GLP-1 유사체 시장 : 지역별, 2020-2032년
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- GCC 국가
- 이스라엘
- 기타 중동
- 아프리카
- 남아프리카
- 북아프리카
- 중앙 아프리카
제13장 경쟁 구도
- Novo Nordisk
- Eli Lilly and Company
- Sanofi
- AstraZeneca
- Boehringer Ingelheim
- Merck & Co.
- Amgen
- GlaxoSmithKline
- Bristol-Myers Squibb
- Takeda Pharmaceutical Company
- Daiichi Sankyo
- Pfizer
- Teva Pharmaceutical Industries
- Regeneron Pharmaceuticals
- Intarcia Therapeutics
- Hngzhou Jiuyuan Gene Engineering Co Ltd
제14장 분석가 추천
- 기회
- 애널리스트의 견해
- Coherent Opportunity Map
제15장 참고문헌과 조사방법
- 참고문헌
- 조사 방법
- 출판사에 대해
Glucagon Like Peptide 1 Analogs Market is estimated to be valued at USD 53.50 Bn in 2025 and is expected to reach USD 104.44 Bn by 2032, growing at a compound annual growth rate (CAGR) of 10.1% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 53.50 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 10.10% | 2032 Value Projection: | USD 104.44 Bn |
The glucagon like peptide 1 analogs market represents a revolutionary segment within the diabetes therapeutics landscape, fundamentally transforming treatment paradigms for Type 2 diabetes mellitus and obesity management. GLP-1 analogs are synthetic versions of the naturally occurring incretin hormone GLP-1, which plays a crucial role in glucose homeostasis by stimulating insulin secretion, suppressing glucagon release, and slowing gastric emptying. These innovative therapeutic agents have emerged as cornerstone treatments due to their dual mechanism of action, offering both glycemic control and significant weight reduction benefits.
The market encompasses various formulations including once-daily, once-weekly, and emerging longer-acting preparations, catering to diverse patient preferences and treatment protocols. Leading pharmaceutical companies have invested heavily in research and development to enhance drug efficacy, reduce side effects, and improve patient compliance through advanced delivery systems. The growing prevalence of diabetes worldwide, coupled with increasing awareness of obesity-related comorbidities, has positioned GLP-1 analogs as preferred therapeutic options among healthcare providers. This market segment continues to witness robust growth driven by expanding clinical applications, including cardiovascular risk reduction and potential neuroprotective effects, making it one of the most dynamic and rapidly evolving sectors in modern pharmaceutical industry.
Market Dynamics
The glucagon like peptide 1 analogs market is propelled by several compelling drivers that underscore its robust growth trajectory. The primary driver is the escalating global prevalence of Type 2 diabetes and obesity, with over 537 million adults currently living with diabetes worldwide, creating an unprecedented demand for effective therapeutic interventions. The superior efficacy profile of GLP-1 analogs, demonstrating significant HbA1c reduction alongside substantial weight loss benefits, positions these agents as preferred treatment options over traditional diabetes medications. Additionally, expanding clinical evidence supporting cardiovascular protective effects and potential applications in non-alcoholic fatty liver disease (NAFLD) broadens the therapeutic scope, driving market adoption. Technological advancements in drug delivery systems, including extended-release formulations and innovative injection devices, enhance patient convenience and adherence, further stimulating market growth. However, the market faces notable restraints, primarily the high cost of GLP-1 analogs compared to conventional diabetes treatments, creating accessibility barriers particularly in price-sensitive markets and limiting insurance coverage in certain regions.
Gastrointestinal side effects, including nausea, vomiting, and diarrhea, can impact patient compliance and treatment continuation, potentially hindering market penetration. Manufacturing complexities associated with peptide-based biologics pose supply chain challenges and cost implications. Nevertheless, significant opportunities emerge from untapped markets in developing economies where diabetes prevalence is rapidly increasing, coupled with improving healthcare infrastructure and expanding insurance coverage. The potential for combination therapies integrating GLP-1 analogs with other diabetes medications presents lucrative development opportunities. Furthermore, ongoing research into novel indications including Alzheimer's disease, Parkinson's disease, and other metabolic disorders could substantially expand the addressable market, positioning GLP-1 analogs as versatile therapeutic platforms beyond diabetes management.
Key Features of the Study
- This report provides an in-depth analysis of the global glucagon like peptide 1 analogs market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global glucagon like peptide 1 analogs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Novo Nordisk, Eli Lilly and Company, Sanofi, AstraZeneca, Boehringer Ingelheim, Merck & Co., Amgen, GlaxoSmithKline, Bristol-Myers Squibb, Takeda Pharmaceutical Company, Daiichi Sankyo, Pfizer, Teva Pharmaceutical Industries, Regeneron Pharmaceuticals, Intarcia Therapeutics, and Hngzhou Jiuyuan Gene Engineering Co Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global glucagon like peptide 1 analogs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
- Drug Type Insights (Revenue, USD Bn, 2020 - 2032)
- Semaglutide
- Liraglutide
- Exenatide
- Dulaglutide
- Tirzepatide
- Others
- Linagliptin
- Lixisenatide
- Brand Insights (Revenue, USD Bn, 2020 - 2032)
- Saxenda
- Victoza
- Ozempic
- Wegovy
- Rybelsus
- Trulicity Pen
- Zepbound
- Mounjaro
- BYDUREON BCise
- Others
- Application Insights (Revenue, USD Bn, 2020 - 2032)
- Type 2 Diabetes Mellitus
- Weight Management (Obesity/Overweight)
- Cardiovascular Risk Reduction
- Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Parenteral
- Type Insights (Revenue, USD Bn, 2020 - 2032)
- Brand
- Generic
- Gender Insights (Revenue, USD Bn, 2020 - 2032)
- Male
- Female
- Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Adult
- Pediatric/Children
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Novo Nordisk
- Eli Lilly and Company
- Sanofi
- AstraZeneca
- Boehringer Ingelheim
- Merck & Co.
- Amgen
- GlaxoSmithKline
- Bristol-Myers Squibb
- Takeda Pharmaceutical Company
- Daiichi Sankyo
- Pfizer
- Teva Pharmaceutical Industries
- Regeneron Pharmaceuticals
- Intarcia Therapeutics
- Hngzhou Jiuyuan Gene Engineering Co Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Glucagon Like Peptide 1 Analogs Market, By Drug Type
- Glucagon Like Peptide 1 Analogs Market, By Brand
- Glucagon Like Peptide 1 Analogs Market, By Application
- Glucagon Like Peptide 1 Analogs Market, By Route of Administration
- Glucagon Like Peptide 1 Analogs Market, By Type
- Glucagon Like Peptide 1 Analogs Market, By Gender
- Glucagon Like Peptide 1 Analogs Market, By Age Group
- Glucagon Like Peptide 1 Analogs Market, By Distribution Channel
- Glucagon Like Peptide 1 Analogs Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Glucagon Like Peptide 1 Analogs Market, By Drug Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Semaglutide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Liraglutide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Exenatide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Dulaglutide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Tirzepatide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Linagliptin
- Lixisenatide
5. Glucagon Like Peptide 1 Analogs Market, By Brand, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Saxenda
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Victoza
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ozempic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Wegovy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Rybelsus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Trulicity Pen
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Zepbound
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Mounjaro
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- BYDUREON BCise
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Glucagon Like Peptide 1 Analogs Market, By Application, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Type 2 Diabetes Mellitus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Weight Management (Obesity/Overweight)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Cardiovascular Risk Reduction
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Glucagon Like Peptide 1 Analogs Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Glucagon Like Peptide 1 Analogs Market, By Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Brand
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Glucagon Like Peptide 1 Analogs Market, By Gender, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Glucagon Like Peptide 1 Analogs Market, By Age Group, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Pediatric/Children
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
11. Glucagon Like Peptide 1 Analogs Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
12. Global Glucagon Like Peptide 1 Analogs Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Brand, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Brand, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Brand, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Brand, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Brand, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Brand, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
13. Competitive Landscape
- Novo Nordisk
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Boehringer Ingelheim
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Daiichi Sankyo
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Regeneron Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Intarcia Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hngzhou Jiuyuan Gene Engineering Co Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
14. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
15. References and Research Methodology
- References
- Research Methodology
- About us
